For: | Cao WH, Zhang YQ, Li XX, Zhang ZY, Li MH. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World J Hepatol 2024; 16(10): 1158-1168 [PMID: 39474576 DOI: 10.4254/wjh.v16.i10.1158] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v16/i10/1158.htm |
Number | Citing Articles |
1 |
Onur Baş, Leyla Sert, Onur Yazdan Balçık, Mert Tokatli, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Şahin, Deniz Can Güven, Zafer Arık, Abdurrahman Işikdoğan, Mustafa Erman. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country. Expert Review of Anticancer Therapy 2025; doi: 10.1080/14737140.2025.2529290
|
2 |
Yuyao Yuan, Donghao Yin, Xuemeng Yang, Di Liu, Hui Shan, Juan Luo, Xiuhui Li, Yuxin Yin. Plasma lipidomic analysis reveals disruption of ether phosphatidylcholine biosynthesis and facilitates early detection of hepatitis B-related hepatocellular carcinoma. Lipids in Health and Disease 2025; 24(1) doi: 10.1186/s12944-025-02475-z
|
3 |
Christina Karampera, Antonio D'Alessio. Not So Quiet on the Viral Front: Low‐Level HBV Viraemia Undermines Immunotherapy in HCC. Liver International 2025; 45(6) doi: 10.1111/liv.70140
|